Judge Your Health

Novo Nordisk is trimming U.S. Listing charges for its blockbuster GLP-1 tablets Wegovy and Ozempic, with cuts of as much as approximately 50% set to take impact on January 1, 2027, decreasing listing expenses to around $675 consistent with month. The move objectives cheaper coverage co-coverage and excessive-deductible plans as opposition from competitors like Eli Lilly’s Mounjaro and Zepbound intensifies. The price discounts come amid the weight reduction and diabetes drug m